Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Roche Holdings ADR RHHBY

Healthcare
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue... see more

Recent & Breaking News (OTCQX:RHHBY)

Roche Diagnostics honored as one of the best places to work in 2018, a Glassdoor Employees' Choice Award winner

PR Newswire December 8, 2017

Genentech’s HEMLIBRA (emicizumab-kxwh) Every Four Weeks Controlled Bleeds in Phase III Study in Hemophilia A

Business Wire December 7, 2017

Phase III IMpower150 Study Showed TECENTRIQ (Atezolizumab) and Avastin (Bevacizumab) Plus Chemotherapy Reduced the Risk of Disease Worsening or Death by 38 Percent for People with a Type of Advanced Lung Cancer

Business Wire December 7, 2017

FDA Grants Genentech’s Avastin Full Approval for Most Aggressive Form of Brain Cancer

Business Wire December 5, 2017

Roche Supports FDA Communication about Potential for Biotin Interference with Lab Tests

PR Newswire December 1, 2017

Roche launches HyperCap Target Enrichment Portfolio, a fully integrated and streamlined NGS sample prep solution for research use

PR Newswire Europe Non Regulatory November 27, 2017

Phase III IMpower150 Study Showed Genentech’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) Plus Chemotherapy Significantly Reduced the Risk of Disease Worsening or Death in the Initial Treatment of People with a Type of Advanced Lung Cancer

Business Wire November 20, 2017

Genentech’s HEMLIBRA (emicizumab-kxwh) Significantly Reduced Bleeds in Phase III Study in Hemophilia A

Business Wire November 20, 2017

FDA Approves Genentech’s Gazyva for Previously Untreated Advanced Follicular Lymphoma

Business Wire November 16, 2017

FDA Approves Genentech’s HEMLIBRA (emicizumab-kxwh) for Hemophilia A with Inhibitors

Business Wire November 16, 2017

Roche launches DISCOVERY Teal HRP chromogen detection kit to advance tissue-based cancer research

PR Newswire November 16, 2017

Roche receives FDA clearance for the VENTANA MMR IHC Panel for patients diagnosed with colorectal cancer

PR Newswire Europe Non Regulatory November 14, 2017

Roche receives FDA approval for VENTANA ALK (D5F3) CDx Assay to identify lung cancer patients eligible for treatment with Roche's ALECENSA (alectinib)

PR Newswire Europe Non Regulatory November 7, 2017

FDA Approves Genentech’s Alecensa (Alectinib) as First-Line Treatment for People With Specific Type of Lung Cancer

Business Wire November 6, 2017

FDA Approves Zelboraf (Vemurafenib) for Erdheim-Chester Disease with BRAF V600 Mutation

Business Wire November 6, 2017

Genentech to Present New Data Across a Range of Blood Diseases at the American Society of Hematology (ASH) 2017 Annual Meeting

Business Wire November 1, 2017

New OCREVUS (Ocrelizumab) Data at ECTRIMS Advance Clinical Understanding of Underlying Progression in Multiple Sclerosis

Business Wire October 27, 2017

FDA Accepts Genentech’s Supplemental Biologics License Application for Avastin as a Front-Line Treatment for Women with Advanced Ovarian Cancer

Business Wire October 26, 2017

Genentech to Present New OCREVUS (Ocrelizumab) Efficacy & Safety Data in Relapsing and Primary Progressive Forms of Multiple Sclerosis at ECTRIMS

Business Wire October 16, 2017

Roche to initiate testing for Babesia parasite at U.S. Blood Centers under FDA Investigational New Drug Application protocol

PR Newswire October 3, 2017